Fortrea Holdings Inc. (FTRE) Stock

Understand Fortrea Holdings Inc.: how it makes money

Fortrea is a contract research organization that runs late-stage clinical trials and provides trial technology (randomization, patient access) for biopharma and medtech clients, billing for professional and technology services. Revenue splits between Clinical Services (trial execution) and Enabling Services (software and patient access), with both tied to pharma R&D spend cycles.

Fortrea's profit is the spread between what pharma pays for late-stage trial execution and the cost of compliant clinical staff, facilities, and technology, a margin that is structurally thin and sensitive to midsized pharma R&D budgets.

Business quality (Weak): Weak: revenue is declining year-over-year, operating margin hovers near 2%, and the business carries the fixed-cost burden of running regulated clinical operations without the pricing power of a dominant CRO.

Bull case

• Scale across two service lines: At $700M in quarterly revenue across clinical trial execution and trial technology, Fortrea holds a meaningful installed base that gives it the scale to absorb a slow pharma spending cycle and still fund its operations.

Bear case

• Top-line contraction: Quarterly revenue of $700M is down 5% year-over-year, a signal that pharma clients are trimming late-stage trial budgets or bringing work in-house, and the decline could persist while R&D spending stays soft.
• Near-zero operating leverage: With operating margin at just 2%, the company is barely covering trial staff, facilities, and technology costs before it reaches the bottom line, so even modest revenue softness flows straight into losses.

Related Companies (Healthcare Services; 8 comparable companies)

• Natera, Inc. (NTRA)
• RadNet, Inc. (RDNT)
• Guardant Health, Inc. (GH)
• Lumexa Imaging Holdings, Inc. Common Stock (LMRI)
• Caris Life Sciences, Inc. (CAI)
• Quest Diagnostics Incorporated (DGX)
• Labcorp Holdings Inc. (LH)
• Veracyte, Inc. (VCYT)